Ivermectin Mass Drug Administratio

Phase 4

Completed

• Conditions: malaria; transmission; ivermectin

• Registration Number: TCTR20210219009
• Lead Sponsor: Mahidol University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-02-19
• Study Completion: 2022-09-23
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 6356

Inclusion Criteria

1. Thai people, both male and female
2. Aged > 6 months for mass blood survey to determine malaria infection
3. Aged between 5 - 80 years for ivermectin administration

Exclusion Criteria

For participation in MDA:
1. Weighing less than 15 kilograms
2. Body Temperature > 37.5 oC
3. Not available for follow-up
4. Known hypersensitivity or anaphylaxis to Ivermectin
5. Known active hepatitis or renal disease
6. Pregnant or lactating women or planning to become pregnant during MDA

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Infection immediately before drug administration (month 0), during drug administration at month (months 1,2), after drug administration (months 3,4) prevalence

Secondary Outcome Measures

Name	Time	Method
Infection two months after drug administration period prevalence